{"analyses":[{"ciLowerLimit":"0.73","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.05","estimateComment":"Reference level = Conventional adjuvant TMZ","groupDescription":"Unmethylated MGMT","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.15","pValueComment":"One-sided significance level = 0.05","paramType":"Hazard Ratio (HR)","paramValue":"0.88","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.66","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.15","estimateComment":"Reference level = Conventional adjuvant TMZ","groupDescription":"Methylated MGMT","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.33","pValueComment":"One-sided significance level = 0.05","paramType":"Hazard Ratio (HR)","paramValue":"0.87","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.3","upperLimit":"5.7","value":"5.1"},{"groupId":"OG001","lowerLimit":"5.5","upperLimit":"6.5","value":"6.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"254"},{"groupId":"OG001","value":"262"}],"units":"Participants"}],"title":"Unmethylated MGMT"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.1","upperLimit":"9.6","value":"6.5"},{"groupId":"OG001","lowerLimit":"7.9","upperLimit":"12.4","value":"10.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"122"}],"units":"Participants"}],"title":"Methylated MGMT"}],"denoms":[{"counts":[{"groupId":"OG000","value":"376"},{"groupId":"OG001","value":"384"}],"units":"Participants"}],"description":"Progression is defined as greater than 25% increase in tumor area (two diameters) provided that the patient has not had his/her dose of steroids decreased since the last evaluation period. Progression-free survival time is defined as time from registration to the date of first progression, death, or last known follow-up (censored). Progression-free survival rates are estimated using the Kaplan-Meier method. A concomitant decrease in steroid dose will rule out a progression designation during the first 2 months after completion of radiation therapy. Tumor tissue submitted at baseline was analyzed to determine MGMT (O\\[6\\]-methylguanine-DNA methyltransferase) promoter methylation status (methylated / unmethylated). Analysis occurred after 647 deaths were reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Concurrent radiation therapy with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle.","id":"OG000","title":"Conventional Adjuvant TMZ"},{"description":"Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle.","id":"OG001","title":"Dose-dense Adjuvant TMZ"}],"paramType":"MEDIAN","populationDescription":"MGMT status was not available for all randomized eligible participants. Therefore, data was only available from 376/411 on the conventional arm and 384/420 on the dose-dense arm.","reportingStatus":"POSTED","timeFrame":"From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.","title":"Median Progression-free Survival Time by MGMT Status","type":"SECONDARY","unitOfMeasure":"months"}